Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Between 6 and 11 years~* Autism Spectrum Disorder~* Attention Deficit Hyperactivity Disorder~* Stimulant medication-free at study entry~* No clinically significant abnormalities that preclude safe participation~* Sufficient developmental level (\~3 yrs)~* Able to keep appointments~* Able to communicate effectively~* Teacher cooperation~Exclusion Criteria:~* Received an investigational medication in the previous 30 days~* Current medication treatment is effective and well-tolerated~* Medical conditions that affect patient safety~* MAOIs within one month~* Hypertension~* Bipolar disorder or psychosis~* Anticonvulsants~* Psychotropic medication or health food supplement~* Tourette Disorder~* Seizure disorder~* Neurological condition~* Structural heart disease

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Methylphenidate Transdermal System (Type: EXPERIMENTAL): 10mg for one week, with weekly stepwise increases to 15mg, 20mg, and 30mg for additional 7 weeks, if symptom reports remained elevated. Titration decreased one stepwise dosage

Based on this trial design, predict the completion outcome and termination type (if applicable).